Triple Agonist · Metabolic & Weight Loss Research · COA Verified
For research and laboratory use only. Not for human consumption. By purchasing, you confirm you are a qualified researcher.
For Research Purposes Only. Not approved for human consumption.
Retatrutide is a synthetic triple hormone receptor agonist peptide developed by Eli Lilly — the first-in-class compound to simultaneously activate GLP-1, GIP, and glucagon receptors. In Phase 3 SURMOUNT trials, Retatrutide achieved unprecedented 24.2% mean weight loss at the 12mg dose over 48 weeks, with 91% of participants achieving ≥15% body weight reduction. It represents the most advanced metabolic peptide in clinical research, offering researchers a unique tool for studying triple-pathway metabolic regulation.
Q: What makes Retatrutide unique?
A: It is the first triple agonist (GLP-1 + GIP + Glucagon) studied in Phase 3 trials. Most metabolic peptides target one receptor; Tirzepatide targets two. Retatrutide targets all three simultaneously.
Q: What were the Phase 3 SURMOUNT-1 results?
A: 2,539 participants: 12mg dose achieved 24.2% mean weight loss; 8mg dose 22.8%; 91% achieved ≥15% reduction at highest dose. Published in NEJM 2023.
Q: How does the glucagon component work?
A: Low-level glucagon receptor activation may increase resting energy expenditure via thermogenesis and enhanced lipolysis — complementing the appetite-suppressing effects of GLP-1 and GIP.
Related Research: Complete Retatrutide Research Guide | 2026 Research Update | Weight Loss Mechanisms | Semaglutide Research Peptide | Tirzepatide Research Peptide | Cagrilintide Research Peptide | What Is Retatrutide? | Are Research Peptides Legal? | What Is a COA? | How to Store Research Peptides
For laboratory research use only. Not for human consumption. Not evaluated by the FDA.
